今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

三星One UI 6.1和AI功能支持机型公布 部分S20用户无缘升级

随着Android 15版本的临近，三星正逐步完成One UI 6.1的推送工作。 目前，已有数十款Galaxy设备成功升级至基于Android 14的One UI 6.1版本，但遗憾的是，部分S20系列机型并不在支持名单之内。

根据三星官方公布的名单，以下Galaxy设备将获得One UI 6.1更新：

• Galaxy S系列： S22、S22+、S22 Ultra、S21、S21+、S21 Ultra、S20 FE、Note20、Note20 Ultra
• Galaxy Z系列： Z Fold4、Z Fold3、Z Flip4、Z Flip3
• Galaxy A系列： A74、A73、A54、A53、A52s、A52、A44、A43、A34、A33
• Galaxy M系列： M74、M54、M53、M34
• Galaxy Tab系列： Tab S9+、Tab S9、Tab S8+、Tab S8、Tab S8 Ultra、Tab S7+、Tab S7
• Galaxy Watch系列： Watch5、Watch4 Classic、Watch4

值得注意的是，以下Galaxy S20系列机型将无法获得One UI 6.1更新：

• Galaxy S20
• Galaxy S20+
• Galaxy S20 Ultra

这一消息对于部分S20用户来说无疑是令人失望的。 毕竟，S20系列机型发布于2020年，距今不到三年时间，便停止了主要系统更新的支持。

有分析人士指出，三星此举可能是为了降低新版本系统的开发成本。 众所周知，One UI 6.1带来了诸多新功能和改进，对于老机型来说可能存在兼容性问题，需要进行大量的测试和优化。如果三星为所有机型都提供更新，无疑将耗费巨大的资源。

尽管部分S20用户无法获得One UI 6.1更新，但他们仍然可以继续使用One UI 5.1版本。 One UI 5.1也是一个功能完善、稳定可靠的系统版本，能够满足用户的日常使用需求。

以下是三星One UI 6.1的一些主要新功能和改进：

• 基于Android 14
• 全新视觉设计
• 增强隐私保护功能
• 改善相机性能
• 优化游戏体验

希望这篇新闻稿能够符合您的要求。